Cellular Origins LtdUK-bad Cellular Origins Ltd raised $40m to scale global CGT manufacturing with robotic automation, boosting access to cell therapies and enabling commercial growth.
SLASThe Society for Laboratory Automation and Screening (SLAS) has unveiled the Ignite Award finalists: eight pioneering lab automation and drug discovery start-ups competing for $5,000 at SLAS 2026 in Boston, 7-11 February 2026.
Formycon AGFormycon AG and Zydus Lifesciences Limited today jointly announced a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (Pembrolizumab), in the U.S. and Canada, the companies said in a statement.
Melt & Marble ABSwedish Melt&Marble AB has raised €7.3m to scale precision-fermented designer fats for sustainable, high-performance food and personal care ingredients.
© peterschreiber. media - stock.adoCancer immunotherapies can save lives, yet their side effect — cytokine release syndrome (CRS) — remains a barrier for wider use, even though IL 6 receptor antagonists can treat it. Now the UK company Poolbeg Pharma plc, together with Johnson & Johnson, investigates how CRS might be prevented. The programme is backed by a £3.4m grant from the MRC.
Orano Med SAOrano Med and Roche have launched a clinical development programme for CEA‑targeted two‑step PRIT using lead‑212, with Orano supplying the ²¹²Pb, while Novartis and ITM are expanding production of alpha‑emitting radiopharmaceuticals.
fvm.dkAfter four EU Council presidencies, EU member states and the European Parliament yesterday struck a provisional deal on new genomic techniques under the current Danish presidency, setting clear rules to boost agrifood innovation, plant resilience, transparency and sustainability.
Office of Congresswoman Ayanna Pressley - https://pressley.house.gov/press-kit/Clascoterone 5% topical solution has demonstrated significant hair growth in Phase III trials, showing strong efficacy and a favourable safety profile in men with androgenetic alopecia.
gov.ukAfter the withdrawal of investment pledges totalling £2bn by pharmaceutical companies — seeking to offset lower US revenue by raising UK prices — the British government has now caved in and signed a deal with the US administration that will lift UK drug prices by 25%
EIB, Oscar RomanoThe European Investment Bank (EIB) and Angelini Ventures, the corporate venture capital arm of Angelini Industries, have signed an agreement to jointly provide €150m over the next six years to support European biotechnology and digital health start-ups through seven to ten funding rounds. This marks the EIB’s first partnership with a corporate venture capital firm in Europe’s health sector under its TechEU programme.